Phenolic compounds from the sclerotia of Inonotus obliquus

A review on the cultivation, bioactive compounds, health-promoting factors and clinical trials of medicinal mushrooms Taiwanofungus camphoratus, Inonotus obliquus and Tropicoporus linteus

Medicinal mushrooms, such as Taiwanofungus camphoratus, Inonotus obliquus, and Tropicoporus linteus, have been used in traditional medicine for therapeutic purposes and promotion of overall health in China and many East Asian countries for centuries. Modern pharmacological studies have demonstrated the large amounts of bioactive constituents (such as polysaccharides, triterpenoids, and phenolic compounds) available in these medicinal mushrooms and their potential therapeutic properties. Due to the rising demand for the health-promoting medicinal mushrooms, various cultivation methods have been explored to combat over-harvesting of the fungi. Evidence of the robust pharmacological properties, including their anticancer, hypoglycemic, hypolipidemic, antioxidant, and antiviral activities, have been provided in various studies, where the health-benefiting properties of the medicinal fungi have been further proven through numerous clinical trials. In this review, the cultivation methods, available bioactive constituents, therapeutic properties, and potential uses of T. camphoratus, I. obliquus and T. linteus are explored.

Sesquiterpenoids and bibenzyl derivative from Dendrobium hercoglossum

Three new sesquiterpenoids, dendrohercoglin A - C (1-3), and one new bibenzyl derivative, dendronbiline D (4), together with nine known sesquiterpenoids (5-13) were isolated from Dendrobium hercoglossum. The structures of the new compounds were elucidated by extensive spectroscopic analysis as well as NMR and ECD calculations. All the compounds were evaluated for their neuroprotective and anti-inflammatory activities. Compounds 2 and 3 increased the H2O2-damaged SH-SY5Y cell viabilities from 43.3% to 58.6% and 68.4%, respectively. Compound 4 exhibited pronounced anti-inflammatory activity with IC50 value of 9.5 ± 0.45 μM which was superior to the reference compound quercetin (IC50: 15.7 ± 0.89 μM).

Inhibitory effect of triterpenoids from the mushroom Inonotus obliquus against α-glucosidase and their interaction: Inhibition kinetics and molecular stimulations

Bioassay-guided fractionation led to the isolation of a series of triterpenoids (1-46) including 12 new ones (1-12) from the mushroom Inonotus obliquus. The structures of all the compounds were elucidated by spectroscopic analysis as well as by comparison with literature data. Triterpenoids 1-3, 6, 7, 16, 24, 25, 27, 38, 43, 44 and 46 showed strong α-glucosidase inhibition, with IC₅₀ values from 11.5 to 81.8 μM. Their structure-activity relationships were discussed. Inonotusol F (24) showed the strongest inhibitory activity and it presented noncompetitive inhibition against α-glucosidase. Molecular docking and molecular dynamics stimulation further demonstrated that GLU302 and PHE298 were key amino acids for the inhibition of inonotusol F (24) towards α-glucosidase. This study indicates the vital role of triterpenoids in explaining hypoglycemic effect of Inonotus obliquus and provides important evidence for further development and utilization of this mushroom.

Phelligridin D from Inonotus obliquus attenuates oxidative stress and accumulation of ECM in mesangial cells under high glucose via activating Nrf2

Diabetic nephropathy (DN) is one of the most common microvascular complications of diabetes mellitus and becomes the financial burden and health problem. Pathogenesis of DN has revealed that high glucose has resulted in the oxidative stress and accumulation of extracellular matrix (ECM). Nuclear factor erythroid 2-related factor 2 (Nrf2) is a transcription factor regulating the expression of anti-oxidant enzymes. Therefore, activating Nrf2 gives a promising approach for the treatment of DN. In the discovery of bioactive phytochemicals targeting DN, we have identified phelligridin D from Inonotus obliquus and explored its protective effects against oxidative stress and accumulation of ECM using mesangial cells under high glucose and potential mechanisms. In addition to inhibiting the self-limited proliferation of mesangial cells cultured in high glucose, phelligridin D can attenuate oxidative stress through reducing reactive oxygen species (ROS) and malondialdehyde (MDA) as well as elevating the activity of superoxide dismutase (SOD) and catalase (CAT). Meanwhile, the major components of ECM including collagen IV, fibronectin and laminin were decreased by phelligridin D via inhibiting the secretion of transforming growth factor-β₁ (TGF-β₁) and downstream connective tissue growth factor (CTGF). Further investigations have revealed phelligridin D activated Nrf2 in mesangial cells under high glucose, which was involved in its protective effects. These findings can provide evidences for the discovery of novel therapy targeting DN and application of I. obliquus in practice.